Pre-made Capromab benchmark antibody (Radiolabelled antibody, anti-FOLH1/GCPII therapeutic antibody, Anti-FGCP/FOLH/GCP2/NAALAD1/PSM/PSMA/mGCP Antibody) for drug discovery and mechanism of action (MOA) research

Cat:GMP-Bios-INN-771

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

SKU GMP-Bios-INN-771 Category Tag

Product Details

Pre-made Capromab benchmark antibody (Radiolabelled antibody, anti-FOLH1/GCPII therapeutic antibody, Anti-FGCP/FOLH/GCP2/NAALAD1/PSM/PSMA/mGCP Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Indium (111In) capromab pendetide (trade name Prostascint) is used to image the extent of prostate cancer.[1] Capromab is a mouse monoclonal antibody which recognizes a protein found on both prostate cancer cells and normal prostate tissue. It is linked to pendetide, a derivative of DTPA.[2] Pendetide acts as a chelating agent for the radionuclide indium-111. Following an intravenous injection of Prostascint, imaging is performed using single-photon emission computed tomography (SPECT).[1]

Products Name (INN Index)

Pre-Made Capromab Biosimilar, Radiolabelled Antibody, Anti-FOLH1/GCPII Antibody: Anti-FGCP/FOLH/GCP2/NAALAD1/PSM/PSMA/mGCP therapeutic antibody

INN Name

capromab

Target

FOLH1

Format

Radiolabelled antibody

Derivation

Mus musculus

Species Reactivity

Human

CH1 Isotype

IgG1 – kappa

VD LC

IgG1 – kappa

Highest_Clin_Trial (Jan '20)

NA

Est. Status

NA

100% SI Structure

NA

99% SI Structure

NA

95-98% SI Structure

NA

Year Proposed

NA

Companies

EUSA?Pharma (Doylestown PA USA)

Conditions Approved

NA

Conditions Active

NA

Conditions Discontinued

NA

Development Tech

NA

Previous Name

NA

Gm Offical Target Name

FOLH1

Package

, ,

Genemeidi Omicron Variant Products
test
Previous slide
Next slide